Abstracts tagged "giant cell arteritis"

Abstract Number: 0518 • ACR Convergence 2020
The Impact of Large Vessel Vasculitis of the Axillary Artery on Cumulative Glucocorticoid Dose and Relapse Rate in Giant Cell Arteritis
Philipp Bosch¹, Christian Dejaco², Wolfgang Schmidt³, Andreas Krause³, Kenny-Davis Schlüter³, Gudrun Pregartner⁴ and Valentin Schaefer⁵, ¹Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, Graz, Austria, ²Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria and Rheumatology Service, Hospital of Bruneck, Bruneck, Italy, Bruneck, Italy, ³Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, ⁴Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria, Graz, Austria, ⁵Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany
Background/Purpose: Prognostic markers for clinical outcomes in giant cell arteritis (GCA) are urgently needed. While large vessel GCA (LV-GCA) has been associated with higher glucocorticoid…
Abstract Number: 1929 • ACR Convergence 2020
Visual Ischemia During Relapse and Follow-up of Giant Cell Arteritis: A Systematic Review
Kubra Bugdayli¹, Patompong Ungprasert², Kenneth Warrington³ and Matthew J. Koster³, ¹Case Western Reserve University MetroHealth Medical Center, Cleveland, ²Cleveland Clinic Foundation, Cleveland, ³Mayo Clinic, Rochester, MN
Background/Purpose: The purpose of this study was to characterize the frequency of visual ischemia (VI) as a manifestation of relapse or during follow-up in patients…
Abstract Number: 1946 • ACR Convergence 2020
Fast-Track Giant Cell Arteritis Clinic Experience in the United States
Mark Matza¹, Minna Kohler², John H. Stone³ and Sebastian Unizony¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Fast-track clinics incorporating ultrasound into the initial evaluation of patients suspected of having giant cell arteritis (GCA) have been implemented throughout Europe leading to…
Abstract Number: 0531 • ACR Convergence 2020
The Prevalence of Systemic Sclerosis, Dermatomyositis/Polymyositis, and Giant Cell Arteritis in the United States by Race and Ethnicity: An Analysis Using Electronic Health Records
Sunali Goonesekera¹, Ankit Bansal¹, Swarali Tadwalkar² and Alison Isherwood³, ¹Decision Resources Group, Part of Clarivate, Boston, MA, ²Decision Resources Group, part of Clarivate, Bangolore, India, ³Decision Resources Group, part of Clarivate, London, United Kingdom
Background/Purpose: Epidemiological studies suggest differences in the prevalence and disease severity of certain autoimmune diseases by race and ethnicity. In this study, we evaluate the…
Abstract Number: 1930 • ACR Convergence 2020
Thirty-Day Readmission Rate in Patients Who Were Initially Admitted for Active Giant Cell Arteritis
Shu Cao¹, Caroline Bresnan², Si Li³, Yichen Wang³ and Yih Chang Lin¹, ¹University of South Florida, Morsani College of Medicine, Tampa, FL, ²University of South Florida, Morsani College of Medicine, Tampa, ³The Wright Center for Graduate Medical Education, Scranton
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis with high potential for morbidity leading to frequent hospitalizations and significant economic burden to the…
Abstract Number: 1947 • ACR Convergence 2020
Risk Factors for Anxiety and Depression in Patients with Giant Cell Arteritis
Joana Martinho¹, André Ponte², Eduardo Dourado³, Nikita Khmelinskii¹, Sara Dias⁴, Sofia Barreira⁵, Ana Rita Cruz-Machado¹, Carla Macieira¹, Vítor Teixeira⁶, Ana Rodrigues⁴, Diogo Telles-Correia⁷, João Eurico Fonseca⁸ and Cristina Ponte¹, ¹Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ²Centro Hospitalar Psiquiátrico de Lisboa, Lisboa, Portugal, Lisbon, Portugal, ³Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Lisboa, Portugal, ⁴EpiDoC Unit, Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School, Universidade NOVA de Lisboa (NMS/UNL), Lisbon, Portugal, ⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, ⁶Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ⁷Serviço de Psiquiatria, Hospital de Santa Maria, CHULN, Lisboa, Portugal, Lisbon, Portugal, ⁸Instituto de Medicina Molecular, Faculdade Medicina Universidade de Lisboa and Centro Hospitalar Universitário Lisboa Norte., Lisboa, Portugal
Background/Purpose: Giant cell arteritis (GCA) is the most common primary vasculitis affecting patients aged above 50 years. Its clinical manifestations such as headache, jaw claudication…
Abstract Number: 0568 • ACR Convergence 2020
Clinical Timelines and Management Delays in Suspected Giant Cell Arteritis
Stephen Slade¹, Cindy Chiu¹, Erin Bauer¹ and Amish Dave¹, ¹Virginia Mason Medical Center, Seattle, WA
Background/Purpose: Giant cell arteritis (GCA), the most common systemic vasculitis, may have diagnostic and treatment delays that can increase risk of vascular complications. Diagnostic color…
Abstract Number: 1931 • ACR Convergence 2020
Effect of Cumulative Glucocorticoid Dose and Inflammation on Weight Change During Treatment of Giant Cell Arteritis
Naomi Serling-Boyd¹, Xiaoqing Fu², Yuqing Zhang³, Sebastian Unizony¹, Zachary Wallace⁴, Hyon Choi⁵ and John H. Stone⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Quincy, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Giant cell arteritis (GCA) is a form of large vessel vasculitis that requires treatment with high-dose, long-term glucocorticoids (GC). Weight gain, among other side-effects…
Abstract Number: 1953 • ACR Convergence 2020
Somatic Mutations in a Single Residue of UBA1 Cause VEXAS, a Severe Adult-Onset Rheumatic Disease Presenting as Relapsing Polychondritis, Polyarteritis Nodosa, or Giant Cell Arteritis
David Beck¹, Marcela Ferrada², Keith Sikora³, Amanda Ombrello⁴, Daniela Ospina Cardona⁵, Nicholas Balanda⁶, Wuhong Pei⁶, Jason Collins⁶, Robert Colbert⁷, Mariana Kaplan⁸, Massimo Gadina⁹, Sinisa Savic¹⁰, Helen Lachmann¹¹, Kyle Retterer¹², Shawn Burgess¹³, William Gahl⁶, Achim Werner⁶, Ivona Aksentijevich¹⁴, Neal S. Young⁶, Katherine R. Calvo⁶, Peter C. Grayson¹⁵ and Daniel Kastner¹⁶, ¹National Human Genome Research Institute, Bethesda, ²Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³National Institutes of Health Clinical Center, Bethesda, MD, ⁴National Human Genome Research Institute/National Institutes of Health, Bethesda, MD, ⁵National Institute of Health, Bethesda, ⁶National Institutes of Health, Bethesda, ⁷Pediatric Clinical Trials Unit and Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ¹⁰University of Leeds, England, United Kingdom, ¹¹National Amyloidosis CenterRoyal Free Campus, Rowland Hill St, London, United Kingdom, ¹²GeneDX, Gaithersburg, ¹³National Institutes of Health, Bethesda, MD, ¹⁴National Human Genome Research Institute, Bethesda, MD, ¹⁵Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, ¹⁶National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD
Background/Purpose: Identifying the causes of adult-onset rheumatic diseases remains a challenge, and limits diagnosis, prognosis, and targeted treatment. We hypothesized that mutations in genes regulating…
Abstract Number: 2649 • 2019 ACR/ARP Annual Meeting
Comparison of Biopsy Proven Giant Cell Arteritis in North America and South Europe: A Population-Based Study
Francesco Muratore¹, Cynthia Crowson ², Luigi Boiardi ³, Ambra Pinelli ⁴, Matthew Koster ⁵, Giovanna Restuccia ¹, Tanaz Kermani ⁶, Eric Matteson ⁷, Carlo Salvarani ⁸ and Kenneth Warrington ⁵, ¹Division of Rheumatology, Azienda Unita’ Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ²Mayo Clinic Rochester, Rochester, ³Division of Rheumatology, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Division of Rheumatology, University of Modena and Reggio Emilia, Reggio Emilia, Italy, ⁵Mayo Clinic Rochester, Rochester, MN, ⁶University of California Los Angeles, Los Angeles, CA, ⁷Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, ⁸Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
Background/Purpose: To compare clinical characteristics, treatment, long-term follow-up and prognosis of two population-based cohorts of patients with biopsy-proven giant cell arteritis (GCA) from North America…
Abstract Number: 2673 • 2019 ACR/ARP Annual Meeting
Presentation and Management of Giant Cell Arteritis in a Real-World Setting (Artemis Study)
Alfred Mahr¹, Eric Hachulla ², Hubert de BOYSSON ³, Nassim Guerroui ⁴, Emmanuel Héron ⁵, Stéphane Vinzio ⁶, Jonathan Broner ⁷, François-Xavier Lapebie ⁸, Martin Michaud ⁹, Laurent Sailler ⁸, Thierry Zenone ¹⁰, Mohamed Djerad ¹¹, Mathieu Jouvray ¹², Emilie Shipley ¹³, Nathalie Tieulie ¹⁴, Isabelle Idier ¹⁵, Marc Paccalin ¹⁶ and Valérie Devauchelle Pensec ¹⁷, ¹Hospital Saint-Louis, University Paris Diderot, Paris, France, ²Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France, ³University Hospital of Caen, Caen, France, ⁴European Hospital of Marseille, Marseille, France, ⁵Quinze-Vingt Hospital, Paris, France, ⁶GHM Grenoble, Grenoble, France, ⁷University Hospital of Nîmes, Nîmes, France, ⁸University Hospital of Toulouse, Toulouse, France, ⁹Joseph Ducuing Hospital, Toulouse, France, ¹⁰Hospital of Valence, Valence, France, ¹¹Hospital of Nevers, Nevers, France, ¹²Hospital of Arras, Arras, France, ¹³Hospital of Dax, Dax, France, ¹⁴University Hospital of Nice, Nice, France, ¹⁵Chugai Pharma France, Paris La Défense, France, ¹⁶University Hospital of Poitiers, Poitiers, France, ¹⁷University Hospital of Brest, Brest, France
Background/Purpose: We have few real-world data on the natural history and care of patients with giant cell arteritis (GCA). The objective of this observational study…
Abstract Number: 2918 • 2019 ACR/ARP Annual Meeting
Metabolic Signatures of Pathogenic T Cells in Medium and Large Vessel Vasculitis
Mitsuhiro Akiyama ¹, Hui Zhang ¹, Ryu Watanabe ¹, Toshihisa Maeda ², Gerald Berry ¹, Jorg Goronzy ¹ and Cornelia Weyand¹, ¹Stanford University, Stanford, CA, ²Matsubara Mayflower Hospital, Kobe, Japan
Background/Purpose: Giant cell arteritis (GCA) is an autoimmune vasculitis that causes aortic arch syndrome, blindnesss, and stroke. Embedded in granulomatous infiltrates, CD4 T cells persist…
Abstract Number: 2650 • 2019 ACR/ARP Annual Meeting
Predictors of Relapse in Giant Cell Arteritis: Data from an International Collaboration
Laure Delaval ¹, Raphael Porcher ², Kenneth Warrington ³, Francesco Muratore ⁴, Cynthia Crowson ⁵, Daniel Blockmans ⁶, Christian Agard ⁷, Alexis Régent ⁸, Maxime Samson ⁹, Loic Guillevin ⁸, Carlo Salvarani ¹⁰ and Benjamin Terrier⁸, ¹Department of Internal Medicine, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Paris, France, Paris, France, ²Hotel Dieu Hospital, Paris, France, ³Mayo Clinic Rochester, Rochester, MN, ⁴Division of Rheumatology, Azienda Unita’ Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁵Mayo Clinic Rochester, Rochester, ⁶Department of General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁷CHU Nantes, Nantes, France, ⁸National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, ⁹Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon ; Université Bourgogne-Franche Comté, INSERM, EFS BFC, UMR1098, F-21000 Dijon, Dijon, France, ¹⁰Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
Background/Purpose: Roughly half of giant-cell arteritis (GCA) patients taking only glucocorticoids (GCs) relapse. The relapse rate seems to reflect, in part, the duration of GC intake, more…
Abstract Number: 2675 • 2019 ACR/ARP Annual Meeting
Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a US-based Electronic Health Records Database
Jennie Best¹, Amanda M. Kong ², Oth Tran ² and Margaret Michalska ¹, ¹Genentech, Inc., South San Francisco, CA, ²IBM Watson Health, Cambridge, MA
Background/Purpose: Oral glucocorticoids (OGC) have been the mainstay of treatment for giant cell arteritis (GCA). However, OGCs are associated with several adverse events (AEs). The…
Abstract Number: 2920 • 2019 ACR/ARP Annual Meeting
Comparison of Arterial Patterns of Disease in Takayasu’s Arteritis and Giant Cell Arteritis
K Bates Gribbons¹, Cristina Ponte ², Anthea Craven ³, David Cuthbertson ⁴, Simon Carette ⁵, Gary S. Hoffman ⁶, Nader A. Khalidi ⁷, Curry L. Koening ⁸, Carol Langford ⁹, Kathleen Maksimowicz-McKinnon ¹⁰, Carol A. McAlear ¹¹, Paul Monach ¹², Larry Moreland ¹³, Christian Pagnoux ¹⁴, Kaitlin Quinn ¹⁵, Joanna Robson ¹⁶, Philip Seo ¹⁷, Antoine Sreih ¹⁸, Ravi Suppiah ¹⁹, Kenneth Warrington ²⁰, Steven Ytterberg ²¹, Raashid Luqmani ³, Richard Watts ²², Peter Merkel ¹⁸ and Peter C. Grayson ²³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Department of Rheumatology, Hospital de Santa Maria, Lisbon, Portugal, ³University of Oxford, Oxford, United Kingdom, ⁴University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, ⁶Cleveland Clinic Foundation, Cleveland, OH, ⁷McMaster University, Hamilton, ON, Canada, ⁸University of Utah Hospital, Salt Lake City, UT, ⁹Cleveland Clinic, Cleveland, OH, ¹⁰Henry Ford Hospital, Wayne State University, Detroit, MI, ¹¹University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, ¹²Brigham and Women's Hospital, Boston, MA, ¹³University of Pittsburgh, PITTSBURGH, PA, ¹⁴Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ¹⁵Georgetown University Hospital/National Institutes of Health, Washington, DC, ¹⁶Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ¹⁷Johns Hopkins Medicine, Baltimore, MD, ¹⁸University of Pennsylvania, Philadelphia, PA, ¹⁹Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ²⁰Mayo Clinic Rochester, Rochester, MN, ²¹Mayo Clinic College of Medicine, Rochester, MN, ²²Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ²³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: Current classification criteria differentiate between Takayasu’s arteritis (TAK) and giant cell arteritis (GCA), the two most common forms of large-vessel vasculitis, based primarily on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.